Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation

PHASE4RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Acute B-cell Lymphoblastic Leukemia
Interventions
DRUG

Blinatumomab

"patients with positive MRD were treated with Blinatumomab 28μg×5-15 days, followed by DLI treatment.~(MNC infusion is about 5×10\^7/kg\~1×10\^8/kg). Patients with hematologic recurrence were given Blinatumomab 9μg D1-4,11.66μg d5-7,28μg Starting from d8 (8 to 21 days in total), followed by DLI treatment (infusion of MNC approximately 5×10\^7/kg\~1×10\^8/kg)."

Trial Locations (1)

450000

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhenzhou

All Listed Sponsors
lead

Suping ZHANG

OTHER